Company Profile
CANbridge Pharmaceuticals Inc., a biopharmaceutical company provides the research, development, and commercialization of therapies for rare diseases and oncology indications globally.
The company offers Hunterase, an enzyme replacement therapy (ERT) for the treatment of Hunter syndrome Livmarli, an oral, minimally-absorbed, reversible ileal bile acid transporter inhibitor for the treatment of alagille syndrome and progressive familial intrahepatic cholestasis.
It also develops CAN106, an anti-C5 mAb for paroxysmal nocturnal hemoglobinuria; and CAN103, a recombinant human ERT for the treatment of gaucher disease. Additionally, it develops CAN107, a fibroblast growth factor 23 (FGF23) blocking antibody for X-linked hypophosphatemia.
Its portfolio also includes CAN104, a recombinant human ERT GLA for fabry disease, CAN105, a bispecific antibody for the treatment of hemophilia A, and CAN204 to treat Duchenne muscular dystrophy.
The company has a license agreement with Mirum Pharmaceuticals, Inc. for the development, manufacture, and commercialization of Livmarli. Founded in 2012, CANbridge Pharmaceuticals is headquartered in Suzhou, China.